1. Angioscopic Evaluation of Stabilizing Effects of an Antilipemic Agent, Bezafibrate, on Coronary Plaques in Patients with Coronary Artery Disease
- Author
-
Tomomitsu Ohshima, Katsumi Yamada, Masahito Kanai, Takashi Hitsumoto, Masaaki Ozegawa, Hiroshi Morio, Junichi Hirose, Yuuko Uchida, Kohei Kawamura, Hiroshi Sakuragawa, Yoshiharu Fujimori, Yasumi Uchida, Kimiko Terasawa, Hirofumi Noike, Michihisa Kaku, Takeshi Sakurai, Hidefumi Ohsawa, Shin Sato, Kaneyuki Aoyagi, Keiichi Tokuhiro, and Kunio Yoshinaga
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Angioscopy ,Coronary Disease ,Coronary Angiography ,Coronary artery disease ,chemistry.chemical_compound ,Oral administration ,Internal medicine ,Humans ,Medicine ,Prospective Studies ,Prospective cohort study ,Triglycerides ,Hypolipidemic Agents ,Chemotherapy ,Bezafibrate ,medicine.diagnostic_test ,business.industry ,Cholesterol ,Cholesterol, HDL ,Middle Aged ,medicine.disease ,Surgery ,Stenosis ,chemistry ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
To evaluate the stabilizing effects of an antilipemic agent, bezafibrate, on coronary plaques, we carried out a prospective angioscopic and angiographic open trial. From April 1997 to December 1998, 24 patients underwent coronary angioscopy of plaques in non-targeted vessels during coronary interventions and then again 6 months later. The patients were divided into control (10 patients, 14 plaques) and bezafibrate (14 patients, 21 plaques) groups. Oral administration of bezafibrate (400 mg/day) was started immediately after the intervention and was continued for 6 months. The vulnerability score was determined based on the angioscopic characteristics of plaques and compared before and 6 months later. Six months later, the vulnerability score was reduced (from 1.6 to 0.8; P
- Published
- 2002
- Full Text
- View/download PDF